Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T01788
|
|||||
| Target Name |
COVID-19 non-structural protein 14 (nsp14)
|
|||||
| Synonyms |
COVID-19 Proofreading exoribonuclease; COVID-19 ExoN; COVID-19 Guanine-N7 methyltransferase
Click to Show/Hide
|
|||||
| Gene Name |
COVID-19 rep
|
|||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | COVID-19 [ICD-11: 1D6Y] | |||||
| Function |
Enzyme possessing two different activities: an exoribonuclease activity acting on both ssRNA and dsRNA in a 3' to 5' direction and a N7-guanine methyltransferase activity. Acts as a proofreading exoribonuclease for RNA replication, thereby lowering The sensitivity of the virus to RNA mutagens.
Click to Show/Hide
|
|||||
| BioChemical Class |
Coronaviruses polyprotein 1ab family
|
|||||
| UniProt ID | ||||||
| EC Number |
EC 3.1.13.-
|
|||||
| Sequence |
AENVTGLFKDCSKVITGLHPTQAPTHLSVDTKFKTEGLCVDIPGIPKDMTYRRLISMMGF
KMNYQVNGYPNMFITREEAIRHVRAWIGFDVEGCHATREAVGTNLPLQLGFSTGVNLVAV PTGYVDTPNNTDFSRVSAKPPPGDQFKHLIPLMYKGLPWNVVRIKIVQMLSDTLKNLSDR VVFVLWAHGFELTSMKYFVKIGPERTCCLCDRRATCFSTASDTYACWHHSIGFDYVYNPF MIDVQQWGFTGNLQSNHDLYCQVHGNAHVASCDAIMTRCLAVHECFVKRVDWTIEYPIIG DELKINAACRKVQHMVVKAALLADKFPVLHDIGNPKAIKCVPQADVEWKFYDAQPCSDKA YKIEELFYSYATHSDKFTDGVCLFWNCNVDRYPANSIVCRFDTRVLSNLNLPGCDGGSLY VNKHAFHTPAFDKSAFVNLKQLPFFYYSDSPCESHGKQVVSDIDYVPLKSATCITRCNLG GAVCRHHANEYRLYLDAYNMMISAGFSLWVYKQFDTYNLWNTFTRLQ Click to Show/Hide
|
|||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: Trapidil | Ligand Info | |||||
| Structure Description | PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z56791867 | PDB:5SMF | ||||
| Method | X-ray diffraction | Resolution | 2.01 Å | Mutation | No | [2] |
| PDB Sequence |
PTHLSVDTKF
33 KTEGLCVDIP43 GIPKDMTYRR53 LISMMGFKMN63 YQVNGYPNMF73 ITREEAIRHV 83 RAWIGFDVEG93 CHGTNLPLQL109 GFSTGVNLVA119 VPTPLMYKGL157 PWNVVRIKIV 167 QMLSDTLKNL177 SDRVVFVLWA187 HGFELTSMKY197 FVKIGPERTC207 CLCDRRATCF 217 STASDTYACW227 HHSIGFDYVY237 NPFMIDVQQW247 GFTGNLQSNH257 DLYCQVHGNA 267 HVASCDAIMT277 RCLAVHECFV287 KRVDWTIEYP297 IIGDELKINA307 ACRKVQHMVV 317 KAALLADKFP327 VLHDIGNPKA337 IKCVPQADVE347 WKFYDAQPCS357 DKAYKIEELF 367 YSYHSDKFTD379 GVCLFWNCNV389 DRYPANSIVC399 RFDTRVLSNL409 NLPGCDGGSL 419 YVNKHAFHTP429 AFDKSAFVNL439 KQLPFFYYSD449 SPCESHGIDY465 VPLKSATCIT 475 RCNLGGAVCR485 HHANEYRLYL495 DAYNMMISAG505 FSLWVYKQFD515 TYNLWNTFT |
|||||
|
|
||||||
| Ligand Name: (2R)-3-(3,5-dimethyl-1,2-oxazol-4-yl)-N,N,2-trimethylpropanamide | Ligand Info | |||||
| Structure Description | PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1246465616 | PDB:5SLD | ||||
| Method | X-ray diffraction | Resolution | 1.58 Å | Mutation | No | [3] |
| PDB Sequence |
PTHLSVDTKF
33 KTEGLCVDIP43 GIPKDMTYRR53 LISMMGFKMN63 YQVNGYPNMF73 ITREEAIRHV 83 RAWIGFDVEG93 CHGTNLPLQL109 GFSTGVNLVA119 VPTPLMYKGL157 PWNVVRIKIV 167 QMLSDTLKNL177 SDRVVFVLWA187 HGFELTSMKY197 FVKIGPERTC207 CLCDRRATCF 217 STASDTYACW227 HHSIGFDYVY237 NPFMIDVQQW247 GFTGNLQSNH257 DLYCQVHGNA 267 HVASCDAIMT277 RCLAVHECFV287 KRVDWTIEYP297 IIGDELKINA307 ACRKVQHMVV 317 KAALLADKFP327 VLHDIGNPKA337 IKCVPQADVE347 WKFYDAQPCS357 DKAYKIEELF 367 YSYHSDKFTD379 GVCLFWNCNV389 DRYPANSIVC399 RFDTRVLSNL409 NLPGCDGGSL 419 YVNKHAFHTP429 AFDKSAFVNL439 KQLPFFYYSD449 SPCESHGIDY465 VPLKSATCIT 475 RCNLGGAVCR485 HHANEYRLYL495 DAYNMMISAG505 FSLWVYKQFD515 TYNLWNTFT |
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. June 5, 2020. | |||||
| REF 2 | PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z56791867 | |||||
| REF 3 | PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1246465616 | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.